State Street
CBIO

State Street’s Crescent Biopharma CBIO Stock Holding History

State Street’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.68M Buy
315,587
+276,520
+708% +$5.4M ﹤0.01% 2950
2026
Q1 		$718K Buy
39,067
+12,850
+49% +$147K ﹤0.01% 3568
2025
Q4 		$311K Buy
26,217
+7,600
+41% +$96.8K ﹤0.01% 3798
2025
Q3 		$221K Buy
+18,617
New +$247K ﹤0.01% 3882
2025
Q2 		– Sell
-1,793
Closed -$37.6K – 4288
2025
Q1 		$37.6K Hold
1,793
– – ﹤0.01% 4135
2024
Q4 		$44.6K Hold
1,793
– – ﹤0.01% 4122
2024
Q3 		$30.3K Hold
1,793
– – ﹤0.01% 4174
2024
Q2 		$50.5K Hold
1,793
– – ﹤0.01% 4135
2024
Q1 		$538K Sell
1,793
-75
-4% -$22.4K ﹤0.01% 3627
2023
Q4 		$441K Hold
1,868
– – ﹤0.01% 3665
2023
Q3 		$280K Hold
1,868
– – ﹤0.01% 3838
2023
Q2 		$325K Hold
1,868
– – ﹤0.01% 3841
2023
Q1 		$235K Buy
1,868
+302
+19% +$68K ﹤0.01% 4020
2022
Q4 		$474K Buy
1,566
+76
+5% +$11.2K ﹤0.01% 3787
2022
Q3 		$82K Hold
1,490
– – ﹤0.01% 4532
2022
Q2 		$89K Hold
1,490
– – ﹤0.01% 4571
2022
Q1 		$170K Buy
1,490
+47
+3% +$5.51K ﹤0.01% 4443
2021
Q4 		$208K Hold
1,443
– – ﹤0.01% 4333
2021
Q3 		$316K Hold
1,443
– – ﹤0.01% 4169
2021
Q2 		$335K Sell
1,443
-5,099
-78% -$1.3M ﹤0.01% 4011
2021
Q1 		$1.97M Sell
6,542
-488
-7% -$175K ﹤0.01% 3446
2020
Q4 		$2.64M Buy
7,030
+309
+5% +$108K ﹤0.01% 3249
2020
Q3 		$2.06M Buy
6,721
+189
+3% +$72.2K ﹤0.01% 3181
2020
Q2 		$2.46M Buy
6,532
+306
+5% +$86.6K ﹤0.01% 3094
2020
Q1 		$1.42M Sell
6,226
-176
-3% -$67.3K ﹤0.01% 3202
2019
Q4 		$3.39M Sell
6,402
-263
-4% -$142K ﹤0.01% 3033
2019
Q3 		$2.87M Sell
6,665
-3,999
-38% -$2.57M ﹤0.01% 3080
2019
Q2 		$12.7M Sell
10,664
-293
-3% -$350K ﹤0.01% 2374
2019
Q1 		$13.7M Sell
10,957
-1,518
-12% -$1.74M ﹤0.01% 2297
2018
Q4 		$11.8M Sell
12,475
-5,089
-29% -$6.12M ﹤0.01% 2341
2018
Q3 		$25.3M Sell
17,564
-1,688
-9% -$2.55M ﹤0.01% 2016
2018
Q2 		$31.1M Buy
19,252
+2,322
+14% +$3.99M ﹤0.01% 1829
2018
Q1 		$27.5M Buy
16,930
+16,593
+4,924% +$34.5M ﹤0.01% 1824
2017
Q4 		$566K Buy
337
+81
+32% +$107K ﹤0.01% 3433
2017
Q3 		$358K Buy
256
+7
+3% +$8.22K ﹤0.01% 3526
2017
Q2 		$278K Sell
249
-1,122
-82% -$927K ﹤0.01% 3506
2017
Q1 		$745K Buy
1,371
+28
+2% +$17.2K ﹤0.01% 3334
2016
Q4 		$819K Buy
1,343
+33
+3% +$20.6K ﹤0.01% 3318
2016
Q3 		$934K Buy
1,310
+279
+27% +$213K ﹤0.01% 3208
2016
Q2 		$751K Buy
+1,031
New +$710K ﹤0.01% 3328
2014
Q2 		– Sell
-562
Closed -$918K – 3654
2014
Q1 		$918K Buy
+562
New +$680K ﹤0.01% 3268

Other funds holding CBIO

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $217M AUM

State Street's CBIO Position: Q2 2026 in Review

State Street increased its Crescent Biopharma (CBIO) stake by 708% in Q2 2026, buying an estimated $5.4M and bringing the position to 315,587 shares worth $5.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2950.

State Street first reported a position in CBIO in Q1 2014 and has held it in 41 quarters since. The position peaked at $31.1M in Q2 2018. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • State Street held 315,587 shares of Crescent Biopharma worth $5.68M as of Q2 2026.
  • State Street bought 276,520 Crescent Biopharma shares in Q2 2026, an estimated $5.4M.
  • Crescent Biopharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2950 holding.
  • State Street first reported a position in Crescent Biopharma in Q1 2014 and has held it in 41 quarters since.
  • State Street's Crescent Biopharma position peaked at $31.1M in Q2 2018.
  • 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.